10-Q: CRISPR Therapeutics AG Q1 2026 Financial Update

CRISPR Therapeutics AG reports Q1 2026 results with increased cash reserves, ongoing R&D investment, and progress in gene-editing therapies.

Summary

• CRISPR Therapeutics AG filed its Q1 2026 Form 10-Q, detailing financial performance and operational updates.
• The company reported total revenue of $1.458 million for the three months ended March 31, 2026, an increase from $865,000 in the prior year period.
• Research and development expenses were $68.6 million, a slight decrease from $72.5 million in Q1 2025, while general and administrative expenses decreased to $17.2 million from $19.3 million.
• The company's net loss for the quarter was $122.9 million, an improvement from a net loss of $136.0 million in the same period last year.
• As of March 31, 2026, CRISPR Therapeutics held $423.3 million in cash and cash equivalents and $2,018.5 million in marketable securities, totaling $2,441.8 million in liquid assets.
• A significant financing event occurred in March 2026 with the issuance of $600.0 million in aggregate principal amount of Convertible Senior Notes due 2031, providing substantial capital.
• The company continues to advance its pipeline of gene-based medicines, including CASGEVY for hemoglobinopathies, in vivo liver editing programs, CAR-T therapies, and regenerative medicine initiatives.
• The company anticipates its current cash, cash equivalents, and marketable securities will fund operations for at least the next 24 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While the company continues to operate at a loss and faces significant R&D costs, the substantial capital raise, improved revenue, and progress in its gene-editing pipeline are positive indicators for future potential.

Positives

• Increased total revenue to $1.458 million in Q1 2026 from $865,000 in Q1 2025.
• Reduced net loss to $122.9 million in Q1 2026 from $136.0 million in Q1 2025.
• Strengthened liquidity with $2,441.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• Successfully raised $600.0 million in March 2026 through the issuance of Convertible Senior Notes due 2031, significantly bolstering capital resources.
• Continued progress in advancing multiple gene-editing therapeutic programs, including CASGEVY, in vivo liver editing, and CAR-T therapies.
• The company expects its current cash reserves to fund operations for at least the next 24 months.

Negatives

• The company continues to incur significant net losses, with a loss of $122.9 million in Q1 2026.
• Research and development expenses remain substantial at $68.6 million, reflecting ongoing investment in pipeline development.
• The company anticipates continued losses and the need for additional capital for future operations and development.
• The fair value of corporate equity securities experienced a negative change of $12.1 million in Q1 2026, impacting other income.

Risks

• The company's indebtedness and liabilities could limit cash flow available for operations and expose it to risks that could adversely affect its business, financial condition, and results of operations.
• The issuance of $600.0 million in Convertible Senior Notes could lead to dilution of existing shareholders' ownership interests upon conversion.
• The outcome of legal proceedings, such as the patent infringement lawsuit initiated by ToolGen, Inc. (from which CRISPR Therapeutics was dismissed), is inherently uncertain and could adversely affect the business.
• The company faces risks associated with the development and commercialization of gene-based medicines, including clinical trial failures, regulatory hurdles, and market acceptance.
• Volatile capital markets and unfavorable macroeconomic conditions could impact the company's ability to raise additional capital.
• The company is subject to risks related to its intellectual property estate, including potential patent infringement claims and the need to maintain and defend its IP.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditures for at least the next 24 months. It anticipates continued losses and the need for additional capital, which may be raised through equity or debt financings, or strategic collaborations. The company's success hinges on developing its technology platform, advancing product candidates through clinical trials, obtaining regulatory approvals, and achieving market acceptance.

Management Comments

• "Our mission is to create transformative gene-based medicines for serious human diseases."
• "We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo approaches, CAR-T and regenerative medicine."
• "CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex."
• "We believe that our innovative research, translational expertise and clinical development experience position us as a leader in the development of CRISPR-based therapeutics."
• "We anticipate that our expenses will increase as we continue our current research programs and development activities."
• "We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect."

Industry Context

StockSavvy.ai notes that CRISPR Therapeutics AG's Q1 2026 filing reflects the intense capital requirements and long development timelines typical of the gene editing and biotechnology sector. The company's focus on transformative therapies, exemplified by CASGEVY, aligns with industry trends towards precision medicine and potential one-time cures for serious diseases. The significant capital raise via convertible notes is a common strategy for companies at this stage to fund extensive R&D and clinical development.

Comparison to Industry Standards

• CRISPR Therapeutics' net loss of $122.9 million in Q1 2026 is substantial but not unusual for a clinical-stage biotechnology company investing heavily in R&D. Companies like Moderna and BioNTech also reported significant losses during their development phases before achieving commercial success.
• The company's cash and marketable securities balance of $2,441.8 million is robust, providing a strong runway. This level of liquidity is comparable to other leading mid-to-late-stage biopharmaceutical companies, enabling sustained investment in complex gene-editing technologies.
• The successful issuance of $600 million in convertible notes demonstrates investor confidence in the company's technology and pipeline, a common financing route for biotech firms seeking non-dilutive (initially) capital for long-term projects, similar to financing strategies employed by companies like Intellia Therapeutics and Editas Medicine.
• The ongoing investment in R&D, representing $68.6 million in Q1 2026, is in line with industry benchmarks for companies pursuing novel therapeutic modalities, where significant upfront investment is required to advance candidates through preclinical and clinical stages.

Legal Proceedings

• In the fourth quarter of 2025, ToolGen, Inc. initiated a lawsuit against the Company and other third parties alleging patent infringement by CASGEVY of a ToolGen patent relating to CRISPR/Cas9 gene editing technology. The Company was subsequently dismissed from the lawsuit as a defendant in April 2026 without prejudice.

Stakeholder Impact

• Shareholders: Potential dilution from conversion of convertible notes and future equity financings. Continued investment in R&D aims for long-term value creation.
• Employees: Continued employment and equity incentives, with stock-based compensation expense recognized.
• Collaborators (e.g., Vertex, Sirius): Ongoing collaboration activities and financial arrangements as detailed in the filing, impacting shared development and commercialization efforts.
• Creditors: The issuance of convertible notes increases the company's debt obligations, impacting its leverage and future repayment capacity.

Next Steps

• Continue advancing CASGEVY in clinical trials for younger patient populations and long-term follow-up.
• Progress in vivo liver editing programs, including CTX310 (Phase 1b), CTX340, CTX321, and CTX460 (IND/CTA-enabling studies).
• Advance CAR-T programs, including zugocabtagene geleucel (zugo-cel) in autoimmune diseases and hematologic malignancies, and explore collaborations.
• Continue development of regenerative medicine programs, such as CTX213 for Type 1 Diabetes.
• Explore additional delivery technologies and next-generation editing modalities.
• Monitor and manage ongoing litigation and intellectual property matters.
• Evaluate opportunities for additional capital raising when market conditions are favorable.

Key Dates

Recommendation

CRISPR Therapeutics AG's Q1 2026 filing shows continued progress in its gene-editing pipeline and a significant capital infusion through convertible notes, which strengthens its financial position. However, the company remains in a pre-revenue, loss-making stage with substantial R&D expenses and inherent clinical and regulatory risks. While the long-term potential is significant, the current financial performance and ongoing development uncertainties warrant a 'hold' recommendation for seasoned investors, pending further clinical data and commercialization milestones.

Keywords

CRISPR Therapeutics, 10-Q, Gene Editing, Biotechnology, Pharmaceuticals, CASGEVY, Vertex Pharmaceuticals, Financial Report, SEC Filing, Clinical Trials, R&D Expenses, Convertible Notes